Published in Drug Week, November 11th, 2005
Some of the data was referenced in a presentation made by the principal investigator for this phase II trial at the World Vaccine Congress.
The phase II trial in RCC is being conducted at the New York-Presbyterian Hospital in New York, USA, under an approved investigational new drug protocol. The principal investigator for the trial is Dr Howard Kaufmann of the New York-Presbyterian Hospital,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.